Journal Home
Search for

Articles in Press

Return to articles in press list

Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs

Robert H. DworkinCorresponding Author Informationemail address, Daniel C. Malone, Christopher J. Panarites, Edward P. Armstrong, Sissi V. Pham§

Received 3 April 2009; received in revised form 17 July 2009; accepted 8 August 2009. published online 23 October 2009.
Corrected Proof

Abstract 

Knowledge of the health care costs associated with neuropathic pain is limited. Existing studies have not directly compared the health care costs of different neuropathic pain conditions, and patients with neuropathic pain have not been compared with control subjects with the same underlying conditions (for example, diabetes). To determine health care costs associated with postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN), patients with these conditions were selected from 2 different administrative databases of health care claims and respectively matched to control subjects who had a diagnosis of herpes zoster without persisting pain or a diagnosis of diabetes without neurological complications using propensity scores for demographic and clinical factors. Total excess health care costs attributable to PHN and painful DPN and excess costs for inpatient care, outpatient/professional services, and pharmacy expenses were calculated. The results indicated that the annual excess health care costs associated with peripheral neuropathic pain in patients of all ages range from approximately $1600 to $7000, depending on the specific pain condition. Total excess health care costs associated with painful DPN were substantially greater than those associated with PHN, which might reflect the great medical comorbidity associated with DPN.

Perspective

The data demonstrate that the health care costs associated with 1 peripheral neuropathic pain condition cannot be extrapolated to other neuropathic pain conditions. The results also increase understanding of the economic burden of PHN and painful DPN and provide a basis for evaluating the impact on health care costs of new interventions for their treatment and prevention.

 Departments of Anesthesiology and Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York

 University of Arizona, Tucson, Arizona and Strategic Therapeutics, LLC, Tucson, Arizona

 NeurogesX, Inc, San Mateo, California

§ Sissi Pham Consulting, Inc, Chapel Hill, North Carolina

Corresponding Author InformationAddress reprint requests to Dr Robert H. Dworkin, Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642.

 Supported by grants from NeurogesX, Inc, to the University of Rochester Office of Continuing Professional Education, IMS Health Inc (formerly Health Benchmarks, Inc), Strategic Therapeutics, and Sissi Pham Consulting, Inc. Dr Dworkin has received research support, consulting fees, or honoraria in the past year from Allergan, Alpharma, Arcion, Astellas, AstraZeneca, BioLineRx, Boehringer Ingelheim, Cara, Cervelo, Durect, Eisai, Endo, Forest, Genzyme, Grünenthal, Johnson & Johnson, KAI Pharmaceuticals, Lilly, Merck, NeurogesX, Neuromed, Nuvo, Ono, Pfizer, Philips Respironics, Sanofi Aventis, Solace, UCB Pharma, US Department of Veterans Affairs, US National Institutes of Health, Wyeth, Xenon, and XTL Biopharmaceuticals and is a Special Government Employee of the US Food and Drug Administration Center for Drug Evaluation and Research; Drs Malone and Armstrong have received consulting fees in the past year from NeurogesX through Strategic Therapeutics; Dr Panarites owns shares of Covance, Johnson & Johnson, and Sanofi-Aventis and is an employee of NeurogesX; and Dr Pham owns shares of Glaxo SmithKline and in the past year has received consulting fees from Bristol-Myers Squibb, General Electric, NeurogesX, and Zelos.

PII: S1526-5900(09)00693-2

doi:10.1016/j.jpain.2009.08.005